Key takeaway: Orchid Pharma Limited held its Q4 FY '26 earnings conference call on May 26, 2026, where management discussed the company's financial performance and strategic initiatives. For Q4 FY '26, standalone revenue was approximately INR 238 crores, showing stability compared to INR 237 crores in Q4 FY '25. EBITDA for the quarter was around INR 42.3 crores, up from INR 40 crores in the previous year. Management noted that the antibiotic industry faced significant pricing pressures, but early signs of recovery were observed in Q4. The merger with Dhanuka Laboratories was highlighted as a strategic move to enhance operational efficiencies and potentially improve EBITDA margins. Management also provided updates on various projects, including the 7ACA project and the commercialization of Exblifep, indicating ongoing discussions for licensing agreements in multiple geographies. Overall, management expressed confidence in the company's strengthened position and future growth potential.

Key takeaway: Orchid Pharma Limited's investor presentation detailed the company's financial performance for the fourth quarter and fiscal year ending March 31, 2026. The presentation reported a slight increase in revenue from operations in Q4-26 compared to Q4-25, while total revenue for FY26 decreased by 12% compared to FY25. Other income saw a significant increase of 117% in Q4-26. The company highlighted its integrated cephalosporin platform and its unique position as India's only USFDA-approved sterile cephalosporin manufacturer. Management noted that the merger nearing completion would enhance operational efficiency and capacity utilization. The presentation emphasized Orchid's commitment to addressing antimicrobial resistance and its plans for future growth, including launching new sterile products in the US market. Overall, the document outlined a strategic focus on building a differentiated long-term position in critical antibiotics.

Key takeaway: Orchid Pharma Limited reported a decline in sales for Q3 FY '26, with INR 207 crores compared to INR 217 crores in the same quarter last year, marking a 5% year-on-year decrease. For the nine-month period, sales totaled INR 574 crores, down 16% from INR 684 crores last year. EBITDA for the quarter was 6%, down from 17% the previous year, attributed to ongoing pricing pressures in the global antibiotics market. Management noted a stable oral to sterile product mix and highlighted a shift in the geographical sales mix, with a decrease in regulated market contributions. Cost optimization measures were implemented, with non-employee costs reduced by approximately 10%. R&D investments increased to 1.5% of sales, focusing on differentiated products. Management expressed cautious optimism about gradual revenue recovery, citing some signs of improvement in January. The earnings call concluded with management emphasizing their commitment to long-term value creation.